U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07111988) titled 'Valbenazine in Obsessive Compulsive Disorder' on Aug. 01.
Brief Summary: The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Obsessive-Compulsive Disorder
Intervention:
DRUG: Valbenazine
Selective vesicular monoamine transporter 2 (VMAT2) inhibitor
DRUG: Placebo
Pill that contains no medicine
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of Chicago
Disclaimer: Curated by HT Syndication....